These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 19479487

  • 1. Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
    Boidot R, Vegran F, Soubeyrand MS, Fumoleau P, Coudert B, Lizard-Nacol S.
    Cancer Invest; 2009 Jun; 27(5):521-8. PubMed ID: 19479487
    [Abstract] [Full Text] [Related]

  • 2. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.
    Oncology; 2011 Jun; 80(3-4):269-77. PubMed ID: 21734419
    [Abstract] [Full Text] [Related]

  • 3. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
    Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G.
    Breast Cancer Res Treat; 2011 Feb; 126(1):109-17. PubMed ID: 21190079
    [Abstract] [Full Text] [Related]

  • 4. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
    Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M.
    Breast; 2007 Feb; 16(1):86-93. PubMed ID: 17010609
    [Abstract] [Full Text] [Related]

  • 5. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M.
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [Abstract] [Full Text] [Related]

  • 6. Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
    Bonneterre J, Révillion F, Desauw C, Blot E, Kramar A, Fournier C, Hornez L, Peyrat JP.
    Oncol Rep; 2013 Jan; 29(1):355-61. PubMed ID: 23117275
    [Abstract] [Full Text] [Related]

  • 7. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [Abstract] [Full Text] [Related]

  • 8. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, Holms F, Eidtmann H, Dietrich K, Just M, Clemens MR, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C.
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H.
    J Clin Oncol; 2012 Jan 01; 30(1):11-8. PubMed ID: 22105826
    [Abstract] [Full Text] [Related]

  • 10. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K, Nakayama T, Kim SJ, Tamaki Y, Noguchi S.
    Eur J Cancer; 2011 Aug 01; 47(12):1779-88. PubMed ID: 21741827
    [Abstract] [Full Text] [Related]

  • 11. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
    Glück S, Ross JS, Royce M, McKenna EF, Perou CM, Avisar E, Wu L.
    Breast Cancer Res Treat; 2012 Apr 01; 132(3):781-91. PubMed ID: 21373875
    [Abstract] [Full Text] [Related]

  • 12. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease.
    Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H.
    Clin Cancer Res; 2004 Oct 01; 10(19):6418-31. PubMed ID: 15475428
    [Abstract] [Full Text] [Related]

  • 13. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S.
    Cancer; 2011 Aug 15; 117(16):3682-90. PubMed ID: 21305539
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
    de Ronde JJ, Lips EH, Mulder L, Vincent AD, Wesseling J, Nieuwland M, Kerkhoven R, Vrancken Peeters MJ, Sonke GS, Rodenhuis S, Wessels LF.
    Breast Cancer Res Treat; 2013 Jan 15; 137(1):213-23. PubMed ID: 23203637
    [Abstract] [Full Text] [Related]

  • 16. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
    Nakamura Y, Oshima K, Naoi Y, Nakayama T, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S.
    Breast Cancer Res Treat; 2012 Jul 15; 134(1):229-36. PubMed ID: 22315133
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.
    Collie-Duguid ES, Sweeney K, Stewart KN, Miller ID, Smyth E, Heys SD.
    Breast Cancer Res Treat; 2012 Apr 15; 132(3):807-18. PubMed ID: 21695460
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.